Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagane, M.
Right arrow Articles by Huang, H.-J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagane, M.
Right arrow Articles by Huang, H.-J. S.
[Cancer Research 60, 847-853, February 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Increased Death Receptor 5 Expression by Chemotherapeutic Agents in Human Gliomas Causes Synergistic Cytotoxicity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Vitro and in Vivo

Motoo Nagane1, Guohua Pan, Jessie J. Weddle, Vishva M. Dixit, Webster K. Cavenee and H.-J. Su Huang

Ludwig Institute for Cancer Research [M. N., W. K. C., H.-J. S. H.], Department of Medicine [W. K. C., H.-J. S. H.], Center for Molecular Genetics [W. K. C.], and Cancer Center [W. K. C.], University of California at San Diego, La Jolla, California 92093-0660; Departments of Endocrinology [G. P.] and Molecular Oncology [V. M. D.], Genentech, Inc., South San Francisco, California 94080-4990; and Department of Molecular Biology, Becton-Dickinson PharMingen, San Diego, California 92121 [J. J. W.]

The intractability of malignant gliomas to multimodality treatments plays a large part in their extremely poor prognosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel member of the tumor necrosis factor (TNF) family that induces apoptosis preferentially in tumor cells through binding to its cognate death receptors, DR4 and DR5. Here we show that the DNA-damaging chemotherapeutic drugs, cis-diamminedichloroplatinum(II) (CDDP) and etoposide, elicited increased expression of DR5 in human glioma cells. Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA. Moreover, systemic in vivo administration of TRAIL with CDDP synergistically suppressed both tumor formation and growth of established s.c. human glioblastoma xenografts in nude mice by inducing apoptosis without causing significant general toxicity. The combination treatment resulted in complete and durable remission in 29% of mice with the established s.c. xenografts and also significantly extended the survival of mice bearing intracerebral xenografts. These results provide preclinical proof-of-principle for a novel therapeutic strategy in which the death ligand, TRAIL, is safely combined with conventional DNA-damaging chemotherapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
P. G. Oliver, A. F. LoBuglio, K. R. Zinn, H. Kim, L. Nan, T. Zhou, W. Wang, and D. J. Buchsbaum
Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11
Clin. Cancer Res., April 1, 2008; 14(7): 2180 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Ziegler, A. L. Kung, and M. W. Kieran
Anti-Apoptosis Mechanisms in Malignant Gliomas
J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev., November 1, 2007; 21(21): 2683 - 2710.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Baritaki, A. Katsman, D. Chatterjee, K. C. Yeung, D. A. Spandidos, and B. Bonavida
Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation
J. Immunol., October 15, 2007; 179(8): 5441 - 5453.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R. Smith, F. Jin, and I. Joshi
Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2
Clin. Cancer Res., September 15, 2007; 13(18): 5528s - 5534s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Liu, P. Yue, S. Chen, L. Hu, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells
Cancer Res., May 15, 2007; 67(10): 4981 - 4988.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Baritaki, S. Huerta-Yepez, T. Sakai, D. A. Spandidos, and B. Bonavida
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1
Mol. Cancer Ther., April 1, 2007; 6(4): 1387 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. C. Lee, D. A. Hamstra, M. S. Bhojani, A. P. Khan, B. D. Ross, and A. Rehemtulla
Noninvasive Molecular Imaging Sheds Light on the Synergy between 5-Fluorouracil and TRAIL/Apo2L for Cancer Therapy
Clin. Cancer Res., March 15, 2007; 13(6): 1839 - 1846.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Gong, D. Yang, S. Kohanim, R. Humphreys, L. Broemeling, and R. Kurzrock
Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies
Mol. Cancer Ther., December 1, 2006; 5(12): 2991 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. van Geelen, J. L. Westra, E. G. de Vries, W. Boersma-van Ek, N. Zwart, H. Hollema, H. M. Boezen, N. H. Mulder, J. T. Plukker, S. de Jong, et al.
Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
J. Clin. Oncol., November 1, 2006; 24(31): 4998 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Matsubara, Y. Mizutani, F. Hongo, H. Nakanishi, Y. Kimura, S. Ushijima, A. Kawauchi, T. Tamura, T. Sakata, and T. Miki
Gene therapy with TRAIL against renal cell carcinoma.
Mol. Cancer Ther., September 1, 2006; 5(9): 2165 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-C. Li, C.-C. Tzeng, J. H. Song, F.-J. Tsia, L.-J. Hsieh, S.-J. Liao, C.-H. Tsai, E. G. Van Meir, C. Hao, and C.-C. Lin
Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy.
Clin. Cancer Res., May 1, 2006; 12(9): 2716 - 2729.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Ricci and W.-X. Zong
Chemotherapeutic approaches for targeting cell death pathways.
Oncologist, April 1, 2006; 11(4): 342 - 357.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Yoshida, T. Sakai, T. Koyano, T.-S. Kam, K. Murata, et al.
Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells
Blood, January 15, 2006; 107(2): 679 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Eramo, R. Pallini, F. Lotti, G. Sette, M. Patti, M. Bartucci, L. Ricci-Vitiani, M. Signore, G. Stassi, L. M. Larocca, et al.
Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction
Cancer Res., December 15, 2005; 65(24): 11469 - 11477.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. M. Kim, J. J. Song, J. Y. An, Y. T. Kwon, and Y. J. Lee
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression
J. Biol. Chem., December 9, 2005; 280(49): 41047 - 41056.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, R. M. Cheung, R. Komaki, B. Fang, and J. Y. Chang
Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non-Small Cell Lung Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6657 - 6668.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R.-X. Shi, C.-N. Ong, and H.-M. Shen
Protein Kinase C Inhibition and X-Linked Inhibitor of Apoptosis Protein Degradation Contribute to the Sensitization Effect of Luteolin on Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Cancer Cells
Cancer Res., September 1, 2005; 65(17): 7815 - 7823.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Klucking, A. S. Collins, and J. A. T. Young
Avian Sarcoma and Leukosis Virus Cytopathic Effect in the Absence of TVB Death Domain Signaling
J. Virol., July 1, 2005; 79(13): 8243 - 8248.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. C. Broaddus, T. B. Dansen, K. S. Abayasiriwardana, S. M. Wilson, A. J. Finch, L. B. Swigart, A. E. Hunt, and G. I. Evan
Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage
J. Biol. Chem., April 1, 2005; 280(13): 12486 - 12493.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Lu, T. Kwan, C. Yu, F. Chen, B. Freedman, J. M. Schafer, E.-J. Lee, J. L. Jameson, V. C. Jordan, and V. L. Cryns
Peroxisome Proliferator-activated Receptor {gamma} Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest
J. Biol. Chem., February 25, 2005; 280(8): 6742 - 6751.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yamamoto, H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al.
Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-{alpha}/5-Fluorouracil against Hepatocellular Carcinoma
Clin. Cancer Res., December 1, 2004; 10(23): 7884 - 7895.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall
Interferon {gamma} Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma
Cancer Res., November 15, 2004; 64(22): 8349 - 8356.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Saito, J. R. Bringas, A. Panner, M. Tamas, R. O. Pieper, M. S. Berger, and K. S. Bankiewicz
Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model
Cancer Res., October 1, 2004; 64(19): 6858 - 6862.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, and W. S. El-Deiry
Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells
J. Biol. Chem., September 17, 2004; 279(38): 40044 - 40052.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
D. C. Spierings, E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong
Tissue Distribution of the Death Ligand TRAIL and Its Receptors
J. Histochem. Cytochem., June 1, 2004; 52(6): 821 - 831.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, and K. Bhalla
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
Cancer Res., April 1, 2004; 64(7): 2580 - 2589.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Waxman and P. S. Schwartz
Harnessing Apoptosis for Improved Anticancer Gene Therapy
Cancer Res., December 15, 2003; 63(24): 8563 - 8572.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Efimova, O. Martinez, A. Lokshin, T. Arima, and B. S. Prabhakar
IG20, a MADD Splice Variant, Increases Cell Susceptibility to {gamma}-Irradiation and Induces Soluble Mediators That Suppress Tumor Cell Growth
Cancer Res., December 15, 2003; 63(24): 8768 - 8776.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, Y. Dai, and S. Grant
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells
Mol. Cancer Ther., December 1, 2003; 2(12): 1273 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao
Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1{beta}-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells
Clin. Cancer Res., September 15, 2003; 9(11): 4255 - 4266.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava
Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo
Cancer Res., September 1, 2003; 63(17): 5390 - 5400.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio
Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model
Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ray and A. Almasan
Apoptosis Induction in Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11
Cancer Res., August 1, 2003; 63(15): 4713 - 4723.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Kim, M. Ajaz, A. Lokshin, and Y. J. Lee
Role of Antiapoptotic Proteins in Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Cisplatin-augmented Apoptosis
Clin. Cancer Res., August 1, 2003; 9(8): 3134 - 3141.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. J. Spierings, E. G. E. de Vries, W. Timens, H. J. M. Groen, H. M. Boezen, and S. de Jong
Expression of TRAIL and TRAIL Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors
Clin. Cancer Res., August 1, 2003; 9(9): 3397 - 3405.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Liu, S. Hilsenbeck, and Y. Gazitt
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
Blood, May 15, 2003; 101(10): 4078 - 4087.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Guo, B. Hu, W. Gu, L. Xu, D. Wang, H.-J. S. Huang, W. K. Cavenee, and S.-Y. Cheng
Platelet-Derived Growth Factor-B Enhances Glioma Angiogenesis by Stimulating Vascular Endothelial Growth Factor Expression in Tumor Endothelia and by Promoting Pericyte Recruitment
Am. J. Pathol., April 1, 2003; 162(4): 1083 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa
Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel
Cancer Res., March 15, 2003; 63(6): 1365 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Naka, K. Sugamura, B. L. Hylander, M. B. Widmer, Y. M. Rustum, and E. A. Repasky
Effects of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Alone and in Combination with Chemotherapeutic Agents on Patients' Colon Tumors Grown in SCID Mice
Cancer Res., October 15, 2002; 62(20): 5800 - 5806.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Tang, Y. J. Sun, E. Half, M. T. Kuo, and F. Sinicrope
Cyclooxygenase-2 Overexpression Inhibits Death Receptor 5 Expression and Confers Resistance to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Colon Cancer Cells
Cancer Res., September 1, 2002; 62(17): 4903 - 4908.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Weber, M. Lu, L. Andera, H. Lahm, N. Gellert, M. W. Fariss, V. Korinek, W. Sattler, D. S. Ucker, A. Terman, et al.
Vitamin E Succinate Is a Potent Novel Antineoplastic Agent with High Selectivity and Cooperativity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2 Ligand) in Vivo
Clin. Cancer Res., March 1, 2002; 8(3): 863 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. Choi, O. Kutsch, J. Park, T. Zhou, D.-W. Seol, and E. N. Benveniste
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induces Caspase-Dependent Interleukin-8 Expression and Apoptosis in Human Astroglioma Cells
Mol. Cell. Biol., February 1, 2002; 22(3): 724 - 736.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. J. Lum, A. A. Pilon, J. Sanchez-Dardon, B. N. Phenix, J. E. Kim, J. Mihowich, K. Jamison, N. Hawley-Foss, D. H. Lynch, and A. D. Badley
Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L
J. Virol., November 15, 2001; 75(22): 11128 - 11136.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Sridhar, A. A. Ali, Y. Liang, M. F. El Etreby, R. W. Lewis, and M. V. Kumar
Differential Expression of Members of the Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand Pathway in Prostate Cancer Cells
Cancer Res., October 1, 2001; 61(19): 7179 - 7183.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Naumann, S. Kugler, H. Wolburg, W. Wick, G. Rascher, J. B. Schulz, E. Conseiller, M. Bahr, and M. Weller
Chimeric Tumor Suppressor 1, a p53-derived Chimeric Tumor Suppressor Gene, Kills p53 Mutant and p53 Wild-type Glioma Cells in Synergy with Irradiation and CD95 Ligand
Cancer Res., August 1, 2001; 61(15): 5833 - 5842.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Blood, August 1, 2001; 98(3): 795 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Demidem, D. Morvan, J. Papon, M. De Latour, and J. C. Madelmont
Cystemustine Induces Redifferentiation of Primary Tumors and Confers Protection against Secondary Tumor Growth in a Melanoma Murine Model
Cancer Res., March 1, 2001; 61(5): 2294 - 2300.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
N. Mitsiades, V. Poulaki, C. Mitsiades, and M. Tsokos
Ewing's Sarcoma Family Tumors Are Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Express Death Receptor 4 and Death Receptor 5
Cancer Res., March 1, 2001; 61(6): 2704 - 2712.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. Hao, F. Beguinot, G. Condorelli, A. Trencia, E. G. Van Meir, V. W. Yong, I. F. Parney, W. H. Roa, and K. C. Petruk
Induction and Intracellular Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Mediated Apotosis in Human Malignant Glioma Cells
Cancer Res., February 1, 2001; 61(3): 1162 - 1170.
[Abstract] [Full Text]

Home page
 BloodHome page
J. Wen, N. Ramadevi, D. Nguyen, C. Perkins, E. Worthington, and K. Bhalla
Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells
Blood, December 1, 2000; 96(12): 3900 - 3906.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Mishima, A. P. Mazar, A. Gown, M. Skelly, X.-D. Ji, X.-D. Wang, T. R. Jones, W. K. Cavenee, and H.-J. S. Huang
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
PNAS, July 18, 2000; 97(15): 8484 - 8489.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2000 by the American Association for Cancer Research.